Trastuzumab silences Sox2.

We demonstrate here through measurement of whole transcription by RNA-sequencing in human breast cancer cells exposed to the ERBB2-targeting agent trastuzumab (Herceptin) silencing of the homeobox transcription factor Sox2 resulting from treatment with trastuzumab.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-10-29
DOI
https://doi.org/10.5281/zenodo.23771923
Primary Topic
HER2/EGFR in Cancer Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
preprint

Trastuzumab silences Sox2.

Shahan Mamoor
Zenodo (CERN European Organization for Nuclear Research)
HER2/EGFR in Cancer Research
preprint

Trastuzumab silences Sox2.

Shahan Mamoor
preprint en

Abstract

We demonstrate here through measurement of whole transcription by RNA-sequencing in human breast cancer cells exposed to the ERBB2-targeting agent trastuzumab (Herceptin) silencing of the homeobox transcription factor Sox2 resulting from treatment with trastuzumab.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Trastuzumab silences Sox2. — Shahan Mamoor · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS